Introduction
============

The prevalence of pituitary adenomas is according to a recent report 94/100 000 ([@bib5]), and prolactinomas are by far the commonest form of pituitary tumors (66%). The incidence of microadenomas in autopsy materials is even higher, 23--27%, and almost 50% of them stain positively for prolactin (PRL; [@bib24]). Female sex is a risk factor for prolactinomas in humans, apparently due to the effects of estradiol (E~2~). This link is supported for example by more common occurrence of these tumors in women ([@bib8], [@bib6]), the increase of their growth during pregnancy ([@bib26]), the stimulating effect of estrogens on PRL secretion ([@bib20], [@bib23]), and the occurrence of lactotroph adenomas in transsexual men during pharmacological estrogen treatment ([@bib27]). Likewise, several rodent models support the role of estrogens in the formation of prolactinomas ([@bib39], [@bib12], [@bib13]). Estrogens are apparently not the only cause, and the role of other possible ovarian hormones and local growth factors in this tumorigenesis is less well defined. Although progesterone (P~4~) receptors are expressed in mouse pituitary lactotroph cells ([@bib38]) and human prolactinomas ([@bib16]), the role of P~4~ in pituitary tumorigenesis remains confusing with reports on both stimulatory and inhibitory effects in rodents ([@bib33], [@bib18]).

Recent studies have elucidated the molecular pathogenesis of pituitary adenomas. Increased activation of the cyclin D1 (CCND1)/cyclin-dependent kinase 4 (CDK4)/retinoblastoma protein (RB)/transcription factor E2F1 pathway, or its suppressed inhibition due to deficiency of *p18* and *p27*, has been shown to play an important role in mouse models of pituitary tumors ([@bib15], [@bib10], [@bib41]). In humans, tissue-specific overexpression of *CCND1*, or decreased expression of *p16*, *p18*, and *p27*, is common in tumors of the pituitary gland ([@bib31], [@bib28]). Recently, overexpression of the high-mobility group protein A2 (HMGA2) in pituitary tumors has been described in mice and men ([@bib9]). This factor binds to the inactive RB/E2F1 complex, displacing histone deacetylase 1 (HDAC1), leading to histone acetylation, opening of the chromatin structure, and stabilizing E2F1 ([@bib9]).

Besides the role of E~2~ in the pathogenesis of pituitary tumors ([@bib12]), E~2~-induced proliferation in breast cancer cells activates c-fos, c-jun, and c-myc ([@bib37], [@bib4]), and in endometrial carcinoma extracellular-signal-related kinase (ERK)1/2 ([@bib17]), leading in both models to upregulation of cyclins D1 and E. Synergism between E~2~ and P~4~ action has been observed in some endocrine tumors. In cultured post-menopausal, hormonally treated breast tissue, E~2~, the synthetic progestin medroxyprogesterone acetate and their combination increase the number of Ki-67-positive cells ([@bib7]), with concomitant increase in CCND1 and p21-positive cells and reduced p27 expression. Whether similar synergism is possible between E~2~ and P~4~ in the pathogenesis of pituitary adenomas has not been studied.

We have reported previously that transgenic (TG) female mice with elevated LH/human choriongonadotropin (hCG) action through the expression of the hCGβ-subunit develop lactotroph adenomas in early adult life, in the face of only a short temporary peripubertal increase in ovarian E~2~ production, but persistently high P~4~ levels ([@bib35]). In the current study, we explore in more detail the role of the high circulating levels of P~4~ in these animals in the growth of the pituitary adenomas and elucidate the molecular mechanisms involved.

Materials and methods
=====================

The transgenic mouse model
--------------------------

TG female mice of the FVB/N strain expressing heterozygously the *hCGβ*-subunit cDNA, driven by the human ubiquitin C promoter, and their genotyping and housing have been described before ([@bib35]). Non-TG littermates were used as controls. The animals were handled, and the experiments were approved in accordance with the local institutional animal care policies.

Treatments, and blood and tissue collections
--------------------------------------------

In the hormone antagonist study, wild-type (WT) and TG female mice were subjected to sham operation (C) or gonadectomy (Gx) at 2 months of age, and thereafter treated with various combinations of tamoxifen (Sigma--Aldrich Co.), mifepristone (Sigma--Aldrich), and bromocriptine (IRA, Sarasota, FL, USA), as described in [Table 1](#tbl1){ref-type="table"}. In the hormone treatment study, WT and TG females were sham operated or gonadectomized at 2 months of age, and thereafter treated up to 4.5 months of age with E~2~ and/or P~4~, as described in [Table 1](#tbl1){ref-type="table"}.

Following treatments, the mice were killed by cervical dislocation between 0800 and 1100 h. Blood was collected by cardiac puncture, and serum was separated by centrifugation and stored at −70 °C until analyzed. Pituitary glands were weighed, fixed in 4% paraformaldehyde or snap-frozen in liquid nitrogen, and stored at −70 °C until needed.

Hormone measurements
--------------------

PRL was measured by RIA as described previously ([@bib2]).

Histological analysis and immunohistochemistry
----------------------------------------------

Paraformaldehyde-fixed pituitaries were cut into 10 μm sections and stained with Harris\' hematoxylin--eosin. Immunohistochemistry was carried out with standard techniques, using commercial monoclonal antibodies against mouse Ki-67, and human CCND1, CDK4, and RB; the sources, dilutions, and protocols used are described in [Supplementary data](#supp1){ref-type="sec"}.

Assessment of cell proliferation
--------------------------------

The density of proliferating cells (DPCs) was calculated by counting the Ki-67-positive nuclei and adjusting the result for the measurement area (mm^2^), using the Leica IM 1000, version 1.02 software (Leica Microsystems AG, Heerbrugg, Switzerland). At least three samples per group and two sections per sample were analyzed. From the 12-month-old TG pituitaries showing macroscopic nodules, proliferation index (PI) was calculated as the percentage of Ki-67-positive cells in the nodular area. To this end, samples were counterstained by hematoxylin, and ten fields at 40× magnification were calculated per nodule. The DPC from the same nodules was also determined.

Quantitative RT-PCR
-------------------

Total pituitary RNA was extracted by the RNeasy mini kit (Qiagen) according to the manufacturer\'s instructions. Prior to quantitative RT-PCR (qRT-PCR), all samples were treated with deoxyribonuclease I (Invitrogen). Expression levels were determined for genes presented in [Supplementary Table 1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article (including the primer pairs, annealing temperatures, and gene bank accession numbers). qRT-PCR analysis was carried out as described previously ([@bib1]). Further details about the methodology and quality control are presented in [Supplementary data](#supp1){ref-type="sec"}.

Primary cell cultures
---------------------

Primary pituitary cell cultures were performed as described earlier, with minor modifications ([@bib30]). Briefly, 3--5 pituitary glands of 5-month-old female hCGβ-TG mice were enzymatically dissociated in PBS containing 1 g/l [d]{.smallcaps}-glucose, 2 g/l collagenase, 1 g/l BSA (Sigma--Aldrich), and 200 μM ascorbic acid (Merck) and 60×10^3^ U/l DNase 1 (Epicentre, Madison, WI, USA) for 40 min in a shaker at 37 °C, followed by trituration to disperse the fragments. Cells were plated in Growth Factor Reduced Matrigel matrix (BD Biosciences, Bedford, MI, USA)-coated 24-well plates in DMEM/F12 medium containing penicillin (50×10^3^ U/l) and streptomycin (50 mg/l; Sigma--Aldrich), 200 μM ascorbic acid, 1 g/l BSA, and 10% FCS for 24 h. The cells were washed with PBS and incubated for 24 h in DMEM/F12 medium containing the antibiotics and 5% dextran-coated charcoal-treated FCS in the presence of E~2~, P~4~, or both. RNA was collected immediately after the experiments (RNeasy mini kit).

Culture of GH3 cells
--------------------

GH3 cells were cultured in high glucose DMEM growth medium (Sigma--Aldrich) supplemented with 10% FCS and 1% penicillin/streptomycin (Invitrogen). Cells were maintained in a 96-well plate (10^4^ cells/well) in growth medium for 8 h, and then cultured overnight using medium supplemented with 2% dextran-coated charcoal-stripped FBS and 1% penicillin/streptomycin.

For the determination of cell proliferation, treatments were performed for 48 h in 2% dextran-coated charcoal-stripped serum containing medium. Control cells were treated with vehicle alone, which never exceeded the final concentration of 0.01% (vol/vol). The steroids were dissolved in either ethanol (E~2~ and P~4~) or dimethyl sulfoxide (mifepristone and dexamethasone (Sigma--Aldrich)) to a concentration of 1 mM, and further diluted in medium to the required concentrations. At the end of the treatment, the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) was performed by adding 20 μl of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethonylphenol)-2-(4-sulphenyl)-2H-tetrazolium salt to each well. The induced color change was measured using a standard 96-well plate reader at 490 nm. In parallel wells, cells were counted by the trypan blue exclusion method.

Statistical analysis
--------------------

Statistical analyses were performed using the SigmaStat 3.1 software (SPSS Inc., Chicago, IL, USA) or the SAS System software version 9.1.3 SP2 (SAS Institute, Gary, NC, USA). One-way ANOVA was used for multiple comparisons followed by Holm--Sidak\'s or Dunn\'s *post-hoc* tests. Student\'s *t*-test was used to analyze differences between two groups. Friedman test, followed by Dunn\'s multiple comparison test, was used to analyze the results of the cell culture experiments. Statistical analyses of pituitary weights and PRL levels in the hormone ablation and replacement experiments were performed by two-way ANOVA and analysis of covariance. Natural log-transformation was used when necessary. Residual was checked for justification of the analyses. For correlation analyses, Pearson product moment correlation was used. For the GH3 cell proliferation experiments, all statistical tests were performed using GraphPad Prism 4 statistical software, version 4.01 (GraphPad Inc., San Diego, CA, USA). Cell proliferation was compared between treatments using two-way ANOVA and within treatment using one-way ANOVA, followed by the *post-hoc* Bonferroni multiple comparison test, where appropriate. All results are presented as mean±[s.e.m]{.smallcaps}. A *P* value \<0.05 was considered statistically significant.

Results
=======

Female hCGβ-TG mice develop after puberty large prolactinomas with high DPCs
----------------------------------------------------------------------------

As shown before ([@bib35]), the female TG mice develop gradually after puberty large multinodular pituitary adenomas, up to 150 mg in weight, and giving rise to high serum PRL levels, up to a mean of 10 mg/l ([Supplementary Figure 1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article). At the age of 10--12 months, all TG females have macroprolactinomas. PRL was the only anterior pituitary hormone detected by immunohistochemistry in the tumorous tissue ([Supplementary Figure 2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article). The distribution of Ki-67-positive cells ([Fig. 1](#fig1){ref-type="fig"}) in the pituitary glands indicated a change from diffuse hyperplasia at 4 months of age to focal adenomatous growth at 6 months of age, and an increase with age in the density and proportion (PI; not shown) of proliferating cells with age ([Fig. 1](#fig1){ref-type="fig"}). At 12 months of age, large nodules of macroprolactinomas were seen with numerous Ki-67-positive cells. The DPCs in the macroadenomas was higher than in the rest of the pituitary gland. No metastasis or local invasion was observed, indicating that the tumors were not malignant.

Hormonal manipulations reveal the importance of elevated P~4~ level in the pituitary tumorigenesis
--------------------------------------------------------------------------------------------------

To evaluate the influence of ovarian hormones on pituitary growth and PRL levels, WT and TG mice were first subjected to hormone antagonist treatments ([Fig. 2](#fig2){ref-type="fig"}A and B) as described in [Table 1](#tbl1){ref-type="table"}. The pituitary weights and serum PRL levels of WT animals did not show significant responses to any of the antagonist treatments. Gx of TG mice at 2 months of age completely abolished both the pituitary growth and increase in PRL levels observed in intact TG mice at 6 months of age. The inhibitory effects of tamoxifen and tamoxifen+mifepristone combination were equal. Somewhat weaker inhibition was found with bromocriptine and mifepristone alone. Short tamoxifen treatment between 1 week and 2 months of age, to block the action of the peripubertal E~2~ peak in TG females ([@bib35]), persistently reduced pituitary weights, and subsequent mifepristone treatment of these mice (2--6 months) showed a trend of a further decrease (*P*=0.08).

The hormone replacement study ([Table 1](#tbl1){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}C and D) was shorter (2--4.5 months), and therefore, the differences between WT and TG mice were smaller than upon hormone ablation. E~2~ treatment increased pituitary weights of Gx WT and TG mice, but not to the size observed in intact TG females. P~4~ alone was without effect, but E~2~+P~4~ combination returned the weights in Gx TG mice to levels similar to intact TG mice. Interestingly, P~4~ had no effect on PRL secretion either alone or in combination with E~2~. This fact, and the finding that P~4~ receptor (*Pgr*) expression was increased by E~2~, but not by P~4~ ([Supplementary Figure 3D](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article), indicated that the P~4~ effect on pituitary growth was not due to its conversion to E~2~.

Ccnd1/Cdk4, E2f1, and Hmga2 are up-regulated, and RB1 is down-regulated, in the adenomatous pituitaries
-------------------------------------------------------------------------------------------------------

A number of candidate genes with putative involvement in the pituitary adenoma formation, selected on the basis of literature, were studied by qRT-PCR for altered expression in the tumors ([Supplementary Table 1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)). Because intact ovaries were necessary for the development of prolactinomas ([@bib35]), genes responsive to ovarian hormones (E~2~ and/or P~4~), and/or involved in cell proliferation and/or tumor promotion, were selected for the screening performed on samples from 6-month-old WT and TG mice. The genes with increased expression in TG mice were subjected to more detailed analysis.

One of the candidate genes, *Ccnd1*, showed gradually increased expression with advancing age of the TG mice, up to 6.1-fold at 12 months of age ([Fig. 3](#fig3){ref-type="fig"}A), in line with the concomitant increases in DPC ([Fig. 1](#fig1){ref-type="fig"}) and pituitary weight ([Supplementary Figure 1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)). Pituitary *E2f1* expression reached its maximum in TG mice at 6 months of age ([Fig. 3](#fig3){ref-type="fig"}B), in good agreement with *Ccnd1* expression (*r*=0.95). *Hmga2* expression also gradually increased in the TG pituitaries ([Fig. 3](#fig3){ref-type="fig"}C).

The CCND1 and CDK4 responses were confirmed by immunohistochemistry ([Fig. 3](#fig3){ref-type="fig"}D). In WT pituitaries, nuclear CCND1 immunoreactivity was present in sporadic cells, whereas in 4--6-month-old TG samples, most cells were prominently stained, and at 12 months, practically all pituitary cell nuclei were positive. The intensity of the nuclear staining for CDK4, the partner of CCND1, followed the same pattern ([Fig. 3](#fig3){ref-type="fig"}D). As an indicator of activity of the CCND1/CDK4 complex, the immunostaining of the downstream effector RB showed an expected reciprocal decline. At 12 months, most TG pituitary cells were RB negative, whereas almost all WT cells presented with positive nuclear RB staining.

The other genes with clearly elevated expression (greater than threefold) in the pituitary tumors, but not studied in further detail, included *Pttg1*, *Fgf2*, *Nupr1*, and *Paqr5* ([Supplementary Table 1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)).

Response of pituitary gene expression to hormone manipulations
--------------------------------------------------------------

We then analyzed the responses of selected genes, with likely involvement in the tumorigenesis, to Gx and hormone antagonist treatments ([Table 1](#tbl1){ref-type="table"}); the results are presented in [Fig. 4](#fig4){ref-type="fig"}. Gx and all antihormone treatments reduced the expression of *Ccnd1* and *E2f1*. The expression of *Hmga2*, a stabilizer of E2F1 ([@bib9]), was suppressed by Gx and mifepristone, but not by bromocriptine. *Pgr* expression was measured because of the putative involvement of P~4~ in the tumorigenesis. Its expression did not differ between the WT and TG females, but was decreased by Gx and slightly increased by bromocriptine. *Galanin* is a marker of lactotrophs and their response to estrogens ([@bib14]), and its expression was highly up-regulated in the TG pituitaries, and dramatically suppressed by Gx, while the other hormone manipulations had smaller decreasing effects. Because of the only slight 2.1-fold overexpression of bone morphogenic protein 4 (*Bmp4*), a known stimulus of prolactinoma growth ([@bib29]), in the TG pituitaries, we also assessed the expression level of noggin (*Nog*), the inhibitor of BMP4 ([Supplementary Table 1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)). Its expression was highly elevated in the TG pituitaries, excluding BMP4 as a likely stimulus of the pituitary tumorigenesis. In the hormone manipulation experiments, the levels of *Nog* and *Gal* expression correlated closely with the pituitary tumor size (not shown). The short-term treatment with tamoxifen was somewhat less effective than the other antagonist treatments.

Additional data on serum P~4~ levels, uterine weights, *Pgr* mRNA expression, and pituitary ESR1 and PGR immunohistochemistry are presented in [Supplementary Figure 3](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1). Responses of the anterior pituitary hormones (at mRNA level) to the hormonal manipulations are presented in [Supplementary Figure 4](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article.

Effect of E~2~, P~4~, and their combination on primary mouse pituitary cells and GH3 cells
------------------------------------------------------------------------------------------

Finally, to obtain further evidence for a direct P~4~ effect on pituitary cell proliferation, we stimulated primary pituitary cells of adult TG females with E~2~, P~4~, and their combination. The concentrations used (E~2~=100 pmol/l and P~4~=100 nmol/l) were similar to those measured in TG female serum ([@bib35]). Only the E~2~+P~4~ combination, but not either hormone alone, induced significant upregulation of *Ccnd1* expression ([Fig. 5](#fig5){ref-type="fig"}A).

We then treated rat somatomammotroph GH3 cells with E~2~, P~4~, and their combinations. When cultured in the presence of a submaximally stimulating concentration of E~2~ (100 pM), 0.1 and 1 nM P~4~ significantly enhanced cell proliferation ([Fig. 5](#fig5){ref-type="fig"}B). P~4~ alone had no effect up to 1000 nM ([Supplementary Figure 6A](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article); neither did it enhance the proliferation effect of the maximally stimulating E~2~ concentration of 1 nM. Mifepristone significantly reduced the effect of E~2~+P~4~ on cell proliferation, further supporting the contributory role of P~4~ in the presence of physiological E~2~ levels. When P~4~ was replaced by dexamethasone, no additive effect on the cell proliferation stimulated by E~2~ was seen ([Supplementary Figure 5B](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article), indicating that the P~4~ effect was unlikely due to the activation of the glucocorticoid receptor. Moreover, both *Esr1*, *Esr2*, and *Pgr* (a and b isoforms) messages ([Supplementary Figure 5D](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)) and PGR protein ([Supplementary Figure 5E](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)) were expressed in the GH3 cells, but neither *CYP17* nor *CYP19* ([Supplementary Figure 5D](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)). Hence, the P~4~ effect can be mediated in GH3 cells through the cognate nuclear receptor, but not through its conversion to E~2~. Finally, phosphorylated forms of ERK and RB proteins were detected in the GH3 cells by western blots ([Supplementary Figure 5E](http://erc.endocrinology-journals.org/cgi/content/full/ERC-10-0016/DC1)), indicating that the same signaling mechanisms as in the pituitary tumors respond to E~2~/P~4~ stimulation in the GH3 cells.

Discussion
==========

We observed in this study that the growth of estrogen-dependent pituitary adenomas in hCG expressing TG mice is amplified by P~4~. This finding was supported by P~4~ effects in cultured primary mouse pituitary cells and in a rat somatomammotroph cell line. The mechanism of the tumor promotion in the presence of P~4~ was found to involve in the activation of CCND1 and HMGA2, which are also activated in human pituitary adenomas ([@bib31], [@bib9]). Hence, the molecular pathogenesis of these murine tumors may have similar features with that of human pituitary adenomas.

In deciphering the mechanism of the tumor-promoting effect of high P~4~ level in the TG mice, it is important to exclude the possibility that the effect of P~4~ is indirect through pituitary or extrapituitary conversion of P~4~ to E~2~, a well-established stimulus of pituitary adenomas. Several of our findings support a direct P~4~ effect. First, the experiments with GH3 cells, not able to convert P~4~ to E~2~, showed the amplifying effect of P~4~ on E~2~-stimulated cell proliferation. Secondly, treatment with the P~4~ (and glucocorticoid) antagonist mifepristone clearly inhibited the pituitary growth. Thirdly, in Gx mice, E~2~+P~4~ combination was more effective in inducing pituitary growth than E~2~ alone. Fourthly, P~4~ alone had no effect on pituitary growth, and showed no estrogenic effects, such as stimulation of PRL secretion or upregulation of pituitary *Pgr* expression, thus excluding the conversion of P~4~ to functionally meaningful levels of E~2~.

The role of E~2~ in the induction of pituitary adenomas is well known ([@bib12]), but that of the other ovarian sex hormone, P~4~, remains controversial. While several previous studies demonstrate the inhibitory effects of P~4~ on the growth and PRL production of normal and tumorous pituitary cells ([@bib11], [@bib32], [@bib34]), there are also studies on stimulatory effects of this steroid, especially in combination with E~2~ ([@bib33], [@bib3], [@bib40], [@bib42]). In contrast, ample evidence shows stimulatory effect of P~4~, and P~4~/E~2~ combination, on the growth other hormone-responsive tumors, such as breast and uterine carcinomas ([@bib4], [@bib36]). The effect observed is intimately dependent on the cell type, timing and dose of treatment, and the effect of P~4~ is often biphasic, with an acute stimulatory effect followed by loss of the effect or inhibition. The stimulatory P~4~ effect may only occur in the presence of physiological E~2~ levels, but not on its own, or when the E~2~ level is supraphysiological.

Additive and synergistic effects of E~2~ and P~4~ are well known on the growth of other hormone-responsive tumors. In the mammary gland and uterine epithelium, E~2~ clearly stimulates cell proliferation, whereas P~4~ has both stimulatory and inhibitory effects ([@bib37]). In contrast, in uterine stroma, P~4~ stimulates cell proliferation both in the presence and in the absence of E~2~ ([@bib22]). The mitogenic effect of E~2~ and P~4~ in breast cancer cells is mediated through increased CCND1--Cdk4 activity ([@bib37], [@bib4], [@bib36]). Both hormones apparently share the same cascade, but because E~2~ upregulates *Pgr* expression, E~2~ priming in fact enhances the P~4~ response.

Mutations, locally produced growth factors and hypothalamic endocrine dysregulation, have been shown to be involved in the pathogenesis of pituitary adenomas. In our mouse model, the hCG-stimulated ovarian steroidogenesis apparently provides a mitotic stimulus to the pituitary gland. Indeed, we found out that P~4~ up-regulated in the TG mice, when exposed to physiological levels of E~2~, the well-established tumorigenic CCND1/CDK4/RB/E2F1 signaling cascade. The same effect of P~4~ was observed in cultures of primary mouse pituitary and rat GH3 cells. Concomitant upregulation of the architectural transcription factor *Hmga2* was found in the pituitary adenoma, in keeping with its established involvement in pituitary tumorigenesis in mice and men ([@bib9]). Hence, CCND1 activation, leading to stimulation of *E2F1* expression, seems to occur by several converging mechanisms in our pituitary adenomas model. One is decreased RB expression, which results in E2F1 activation, the other is upregulation of HMGA2, which displaces HDAC1 from the inactive pRB/E2F1 complex, resulting in the acetylation and activation of the latter ([@bib9]). In addition, we found in GH3 cells increased RB phosphorylation, which results in inactivation of this protein and enhanced cyclin D stimulation of E2F1.

CCND1 is a known target of the MAPK/ERK signaling pathway, and continued *Ccnd1* expression requires sustained MAPK activation ([@bib19]). Cross-talk between ESR1 and PGR has shown to be mediated through the SRC/P21ras/ERK pathway in human breast cancer cells ([@bib25]). Dopamine D2 receptors mediate their inhibitory signaling through inactivation of ERK1/2 ([@bib21]), explaining why bromocriptine treatment down-regulated *Ccnd1*. Tamoxifen, bromocriptine, and mifepristone treatments also down-regulated *Ccnd1* expression, suggesting that the upregulation of pituitary *Ccnd1* expression in TG females could occur through cross-talk between normal E~2~ and high P~4~ levels, and decreased dopaminergic tone. Similar responses were observed with the downstream effector *E2f1*, in agreement with a recent report that CCND1 can recruit its own promoter through the RB/E2F pathway after ESR1/PGR activation ([@bib4]). The role of P~4~ was further confirmed in cultured primary pituitary cells showing that only the E~2~/P~4~ combination induced *Ccnd1* expression. This finding indicates the importance of cross-talk between E~2~ and P~4~ also in the pituitary gland. Further evidence for the direct P~4~ action on pituitary cell proliferation, in the presence of physiological E~2~ concentration, was provided by the GH3 cell culture, in connection with RB inactivation and ERK activation, both through P~4~-stimulated phosphorylation.

A potential weakness of this study is the physiological relevance of the highly elevated hormonal responses evoked by hCGβ expression in these animals. This in particular concerns the high P~4~ levels, about 200 nmol/l vs \<10 nmol/l in WT controls, at the time of onset of tumor growth (19), which are about an order of magnitude higher than in human luteal phase. Assuming that the tumorigenic P~4~ effect is dose-dependent, the macroprolactinomas in the TG mice represent responses to a high dose. Smaller, but still significant, tumorigenic effects of P~4~ are likely to occur at lower levels that are more relevant to human physiology. Our results provide a hypothesis for testing the efficacy of mifepristone as an adjuvant in the treatment of bromocriptine resistant prolactinomas.

In conclusion, we have demonstrated an amplifying effect of P~4~ on the growth of E~2~-induced pituitary tumors in female TG mice exposed to high levels of bioactive LH/hCG. It appears that in the presence of normal E~2~ levels, the CCND1/CDK4/RB/E2F1 pathway can be directly enhanced by P~4~, with concomitant activation of several oncogenes, including *Hmga2* and *E2f1*, and downregulation/inactivation of RB. Taken the importance of P~4~ in all reproductive functions of the female, and as a component of numerous medications (including contraceptive and hormone replacement therapy regimens), it may be important to address its potential role in the formation and treatment of pituitary adenomas.
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![Immunohistochemical evaluation of Ki-67 expression and density of proliferating cells in the pituitary glands of wild-type (WT) and transgenic (TG) female mice. Representative immunohistochemical images of Ki-67 staining are shown in 6-month-old WT, and 4-, 6-, and 12-month-old TG mouse samples. The arrowheads indicate Ki-67-positive cells. A large part of the 12-month-old TG sample comprises a macroprolactinoma with numerous Ki-67-positive cells. Scale bars are 100 μm, and the insets are larger magnifications of the same samples (scale bar=25 μm). Numeric data on density of proliferating cells/mm^2^ in the pituitary glands are presented on the right side. The WT values are the mean of the 4-, 6-, and 12-month-old mice. Different superscript letters indicate that these groups differ significantly (*P*\<0.05); three to seven mice were analyzed per group (mean±[s.e.m.]{.smallcaps}), and at least two sections were calculated per specimen. Full colour version of this figure available via <http://dx.doi.org/10.1677/ERC-10-0016>.](ERC100016f01){#fig1}

![Pituitary weights and serum PRL concentrations in the WT and TG mice, and their responses to hormonal manipulations in the antagonist treatment (A and B) and hormone treatment (C and D) experiments, as explained in [Table 1](#tbl1){ref-type="table"}. Pituitary weights (A and C) and serum PRL levels (B and D) of WT control (open bars) and TG (filled bars) mice were measured (mean±[s.e.m.]{.smallcaps}; 5--16 mice/group). In A and B, the data are obtained from 6-month-old mice gonadectomized (Gx) or sham-operated (C) at 2 months of age, followed by treatment between 2 and 6 months of age with bromocriptine (Br), mifepristone (Mf), tamoxifen (Tx), or Mf+Tx combination. In addition, one group of mice received short Tx treatment between 2 weeks and 2 months (sTx; to abolish the peripubertal E~2~ peak), and in one group, the latter was followed by a 2--6-month-treatment with Mf (sTxMf). In C and D, the data are obtained from 4.5-month-old mice with Gx at 2 months of age, followed by 2.5-month treatments with vehicle (Gx), E~2~ (Gx+E~2~), P~4~ (Gx+P~4~), or their combination (Gx+E~2~P~4~). For marking of statistical differences, each bar is provided by superscript letters. If all letters between two bars are different (e.g. ab and cd), then they differ significantly at *P*\<0.05. If any of the superscript letters of two bars is the same (e.g. ab and bc), then there is no statistically significant difference between them.](ERC100016f02){#fig2}

![Pituitary expression of *Ccnd1*, *E2f1*, *Hmga2*, CDK4, and RB in WT and TG female mice. (A--C) depict the levels of *Ccnd1*, *E2fi*, and *Hmga2* respectively as measured by qRT-PCR, in WT (open bars) and TG (filled bars) mice at 2, 4, 6, and 12 months of age (mean±[s.e.m.]{.smallcaps} of 4--6 mice/group). Bars with different superscript letters differ significantly (*P*\<0.05). (D) Shows representative micrographs of CCND1, CDK4, and RB immunohistochemistry of WT and TG mice at the ages (mo) indicated. The arrows indicate nuclei positive for the respective stainings. Note the weak nuclear staining of CCND1 and CDK4 in WT mice. Similar expression patterns were observed with CCND1 and CDK4. The bottom row of panels presents RB expression, which shows strong nuclear staining in WT but weak in TG mice, especially in older ages. The scale bars are 25 μm in the insets. Full colour version of this figure available via <http://dx.doi.org/10.1677/ERC-10-0016>.](ERC100016f03){#fig3}

![Pituitary expression levels of selected genes in WT and TG mice, and their responses to hormonal manipulations. The genes studied were *Ccnd1* (A), *E2f1* (B), *Hmga2* (C), *Pgr* (D), *Gal* (E), and *Nog* (F). For treatments and abbreviations, see [Table 1](#tbl1){ref-type="table"}, antagonist treatments. The results shown are mean±[s.e.m.]{.smallcaps} of 3--5 mice per group. Bars with different superscript letters differ significantly (*P*\<0.05).](ERC100016f04){#fig4}

![Effects of E~2~, P~4~, and their combinations on cell proliferation and signaling in primary mouse pituitary cells and rat somatomammotroph GH3 cells. (A) Expression of *Ccnd1* mRNA in primary pituitary cells isolated from 5-month-old TG mice and stimulated for 24 h as indicated. The results are mean±[s.e.m.]{.smallcaps} of five individual experiments. Different letters indicate significant differences (*P*\<0.05) between the treatment groups. (B) Effects of 48 h P~4~ stimulation on GH3 cell proliferation when co-treated with E~2~ and/or mifepristone (Mf). The mean cell number in controls was taken as 100%, and those of the other treatments were related to this figure (mean±[s.e.m.]{.smallcaps} of 5--6 independent experiments). \**P*\<0.05, \*\**P*\<0.01 versus basal plus 100 pM E~2~; ^†^*P*\<0.05, ^††^*P*\<0.01 vs 0.1 nM P~4~; ^‡^*P*\<0.05, ^‡‡^*P*\<0.01 vs 1 nM P~4~; ^§^*P*\<0.01 vs 0.1 and 1 nM P~4~+1000 pM E~2~+10 μM Mf.](ERC100016f05){#fig5}

###### 

The treatment schemes with hormone antagonists and hormones

  **Treatment**                   **Abbreviation**   **Gonadectomy** (age)   **Treatment period**
  ------------------------------- ------------------ ----------------------- -----------------------
  Antagonist treatments                                                      
   Control (no treatment)         C                  --                      --
   Bromocriptine                  Br                 --                      2--6 months
   Mifepristone                   Mf                 --                      2--6 months
   Tamoxifen                      Tx                 --                      2--6 months
   Mifepristone+tamoxifen         MfTx               --                      2--6 months
   Short tamoxifen                sTx                --                      7 days--2 months
   Short tamoxifen+mifepristone   sTxMf              --                      7 days--2 months (Tx)
                                                                             2--6 months (Mf)
   Gonadectomy                    Gx                 2 months                
  Hormone treatments                                                         
   Control (no treatment)         C                  2 months                2--4.5 months
   Gx+estradiol                   Gx+E~2~            2 months                2--4.5 months
   Gx+progesterone                Gx+P~4~            2 months                2--4.5 months
   Gx+estradiol+progesterone      Gx+E~2~/P~4~       2 months                2--4.5 months

Tx was administered as a 1cm long subcutaneous silastic tubes, and progesterone and mifepristone were administered as 2 cm long subcutaneous silastic tubes (inner diameter 1.58 mm/outer diameter 2.41 mm; Dow Corning, Midland, MI, USA) with both ends sealed with silastic adhesive (Elastocil RTV-1 Silicone Rubber, Wacker-Chemis GmBH, Munich, Germany). Bromocriptine and estradiol were administered as commercial subcutaneous pellets, and changed every 80--90 days after the initial implantation. Progesterone was administered in a 1cm subcutaneous silastic tube. The mice in the short tamoxifen and tamoxifen+mifepristone experiments received tamoxifen by daily injections (10 mg/kg body weight s.c.) between 7 and 21 days, thereafter by silastic tubes until 2 months. All mice were killed at the end of the treatment periods.
